Abstract
Introduction

The manifestation of back pain is contributed by structural, psychosocial and occupational influences [1]. Biochemical and inflammatory factors contribute to the transition of acute towards chronic pain and genetic factors may modulate any of these factors. Research has been mainly focused on genes that determine bone and cartilage structure and are accompanied by morphological signs in magnetic resonance imaging (MRI). Genetic associations were found for disc height narrowing and different definitions of back pain, such as duration of the worst back pain episode and hospitalization for back problems
. The heritability estimates for these back pain variables ranged from 30% to 45% [2] .
However, only a minority of the genetic influences was caused by genes affecting disc degeneration suggesting that genes involved in pain perception, signalling and psychological processing [3] and genetic variants of immune genes [4] contribute to the proportion of heritability of chronic back pain. Individuals vary widely in their sensation and experience of pain [5, 6] and the risk of developing chronic back pain. This inter-individual variability which is partly due to genetic differences in pain signalling molecules would require an individualized pain management which is hampered by the still limited pharmacological treatment options. The genetic variability in the pharmacodynamic and kinetic effects of analgesic agents further contribute to the variable risk of developing chronic back pain because it may interfere with treatment strategies or cause unexpected drug toxicity. In this review, we will summarize genetic factors that specifically modify intervertebral disc stability, pain signalling and analgesic drug metabolism that may independently impact on the risk of developing chronic back pain.
Genetic polymorphisms associated with intervertebral disc disease (IDD)
IDD is characterized by disc degeneration and herniation and is often associated with low back pain and lumbar radicular pain due to nerve root compression or inflammation. Sensory neurons and sensory fibres from multiple spinal cord levels innervate intervertebral discs [7] explaining the often widespread back pain. An increased risk of low back pain was found in relation to all signs of disc degeneration [8, 9] . However, morphological signs alone are of limited predictive value for chronic back pain. [10, 16, 17, [19] [20] [21] . Several IDD associated COL9A2 alleles were identified. The so called Trp2 allele representing a Gln326Trp amino acid exchange in the ␣2 chain was associated with premature disc degeneration and back pain in Finnish, Japanese and Chinese populations [11, 16, 17, 19] . The Trp2 variant however, was not detected in Germans [20] or Greek [18] but a high relapse rate of lumbar disc disease after surgery was detected in carriers of the Gln326Arg variant of collagen IX (COL9A2 ) [20] . The COL9A3 variant associated with lumbar disc disease is also characterized by an amino acid exchange from arginine to tryptophan, the so-called Trp3 variant [10, 13, 14] [118] . However, mostly ␦-opioid receptor gene polymorphisms were associated with substance dependence [119] or psychiatric disorders [120] .
Genetic variants of the genes encoding molecules of extracellular matrix proteins and other structural proteins have been associated with MRI correlates of degenerative disc disease [10-15] and with chronic low back pain with lumbar radicular pain [16-18]. Collagen is a major component of the extracellular matrix and regulates cartilage fibril formation within intervertebral discs. It is a heterotrimeric protein consisting of three ␣-chains. Polymorphisms in the gene coding for the ␣2 and ␣3 chains of collagen IX, COL9A2 and COL9A3 were associated with alterations in the mechanical properties of human intervertebral discs and contribute to the susceptibility for lumbar disc herniation and back pain
Endogenous cannabinoids (CBs), cannabis and its congeners reduce pain and modify emotional components of pain through agonistic action at peripheral and central CB-1 receptors [121, 122] . CBs additionally modify the immune response through CB-2 receptors. The immune modulation by CBs ameliorates inflammatory processes including neuro-immune responses that contribute to the manifestation and chronicity of neuropathic pain [123, 124] . Tetrahydrocannabinol, one of the constituents of marihuana has the potential to reduce serious neuropathic pain in patients with multiple sclerosis or other neuropathic pain syndromes [125] . However, polymorphisms in the CB-1 gene CNR1 have not been associated with specific pain phenotypes, but were found to be associated with obesity [126, 127] , schizophrenia or efficacy of neuroleptic treatment [128, 129] and drug and alcohol dependence [130] [131] [132] . Polymorphisms in the CB-2 gene CNR2 play a role in osteoporosis [133] and thereby possibly chronic back pain that is often caused by osteoporosis of the spine with and without vertebral fractures. Genetic variances in CNR2 might also modulate the susceptibility to autoimmune disorders [134] . The endocannabinoid anandamide is rapidly re-uptaken through a CB transporter and then metabolized by FAAH [135] . Inhibitors of FAAH prolong the half-life of anandamide and other endocannabinoids and potently reduce pain in rodent models [136, 137] . Polymorphisms in the FAAH gene [138] cause an amino acid exchange from proline to threonine at position 129 and result in decreased FAAH enzyme catalytic activity [90] . This P129T mutation was associated with slightly reduced sensitivity to cold pain in experimental settings in healthy volunteers [90] . The potential modulation of the susceptibility to chronic back pain has not been addressed. However, considering the functions of endocannabinoids on bone formation and density and pain signalling [139, 140] it is likely that alterations in their metabolism affect the susceptibility to chronic back pain.
Polymorphisms contributing to chronic widespread musculoskeletal pain
Chronic back pain is often associated with widespread pain in complex musculoskeletal pain syndromes such as fibromyalgia [141] , TMD [142] and chronic fatigue syndrome [143] . Fibromyalgia is a generalized widespread chronic pain disorder characterized by diffuse muscle pain throughout the body, most often including chronic back and neck pain, muscle weakness, fatigue, increased negative mood, sleep disturbance [141] and comorbidity with anxiety and depression [144] . [146, 147] and Spanish fibromyalgia patients carrying a haploype of COMT associated with high pain intensity (rs6269, rs4818 and rs4680) had a higher risk for fibromyalgia and showed higher pain intensities [148] . [149, 150] [159, 160] ; [161, 162] [166, 167] and (vi) the HSAN-V caused by mutations in the nerve growth factor, ␤ polypeptide gene [168] . All these syndromes are very rare, affecting a few families. Therefore, their specific association with back pain has not been shown but it is reasonable to assume that patients with these syndromes will not develop back pain.
Chronic widespread pain is common in the general population. The precise role of genetic factors in the etiopathology is still unclear but polymorphisms in genes of the serotoninergic and catecholaminergic systems have been associated with an increased risk of fibromyalgia and chronic fatigue syndrome. Polymorphisms in the monoamine oxidase A (MAOA) which is one of the enzymes metabolizing serotonin were reported to affect the rate of serotonin degradation and may therefore impact on the risk of psychopathological symptoms which are associated with fibromyalgia, other chronic widespread pain syndromes and chronic back pain [145]. COMT polymorphisms may further contribute to the pathogenesis because approximately 74% of fibromyalgia patients had low or intermediate COMT activity resulting in low catecholamine degradation
Polyarthropathic diseases such as ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis or systemic lupus erythematosus cause inflammatory back pain due to arthritis of the small intervertebral or sacroiliacal joints and myositis. Polymorphisms in the major histocompatibility complex molecules contribute to the development of these diseases
, (iv) the HSAN-III due to mutations in the inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein gene [163-165], (v) the HSAN-IV, also called congenital insensitivity to pain with anhidrosis and based on mutations in the neurotrophic tyrosine kinase, receptor, type 1 gene
Polymorphisms modulating the metabolism of analgesics
Early effective and safe pain therapy may help to prevent the transition to chronic pain [169] and drug-related secondary problems. [170, 171] . Codeine ineffectiveness is partly caused by the lack of formation of its active metabolite morphine, which has a 200-times higher affinity and intrinsic activity at -opioid receptors than codeine itself [172, 173] and is therefore considered the active principle of codeine despite some evidence that codeine or codeine-6-glucuronide contribute to the pharmacodynamic effects [174] [175] [176] [177] [178] . In approximately 7% of the Caucasian population, the CYP2D6 enzyme catabolizing codeine O-demethylation to morphine [179] is known to be inactive for genetic reasons [180] , with differences in other ethnicities [181] , and in these individuals codeine fails to produce relevant clinical analgesia [182, 183] . On the other hand, also in approximately 7% of the Caucasian population, CYP2D6 is extremely active [181, 184] leading to very high morphine formation from codeine. This challenges the safety of codeine therapy as indicated by reported clinical cases of codeine-caused euphoria, dizziness, blurred vision [185] , severe deterioration of consciousness [186] , apnea with subsequent brain damage [187] up to fatal poisoning of breastfed infants [188] . Tramadol metabolism by CYP2D6 also produces an [190] [191] [192] . However, increased opioid effects in a single clinical case have also been interpreted as an indication for the occurrence of tramadol induced toxicity in a CYP2D6 ultra rapid metabolizer [193] . Genetic variants in CYP2C9 associated with reduced function (CYP2C9 alleles *2 and *3) [194] may decrease the metabolic clearance of CYP2C9 substrates, such as some non-steroidal antiinflammatory drugs (NSAIDs). However, probably due to the wide therapeutic range of NSAIDs, increased plasma concentrations of celecoxib, diclofenac or ibuprofen observed in CYP2C9 poor metabolizers [195, 196] appear not to impact the anti-inflammatory or analgesic effects of these drugs. Nevertheless, a case-control study suggested an increased risk of gastroduodenal bleeding in patients with a poor metabolizer CYP2C9 phenotype when they were treated with NSAIDs metabolized by CYP2C9 [197] . Finally, CYP2C8 polymorphisms have been proposed to enhance the formation of reactive metabolites of diclofenac that were associated with an increased risk of diclofenac-evoked liver toxicity [198] .
Polymorphisms in drug metabolizing enzymes may therefore be important for the long-term outcome of back problems. The cytochrome P450 (CYP) isoenzyme 2D6 metabolizes some opioid analgesics, most importantly codeine and tramadol, but also amitriptyline that is often used as a co-analgesic in patients with neuropathic pain and might have some limited usefulness in lumbar root pain
Summary
Several genetic factors contribute to the risk for chronic back pain and widespread pain syndromes ( 
